IlluminOss Receives Patent Office OK
Biloine W. Young • Tue, April 15th, 2014
The U.S. Patent and Trademark Office has issued a Notice of Allowance to IlluminOss Medical Inc. for the company’s Photodynamic Bone Stabilization System (PBSS). The IlluminOss devices are limited by federal law to Investigational Use and are not approved for sale in the USA.
According to the company’s description, the minimally invasive PBSS stabilizes bone fractures or prevents impending fractures through its percutaneous, patient customized fracture fixation system. Using PBSS, clinicians insert an angioplasty-like balloon into the intramedullary canal across the fracture site, which is then filled with a liquid monomer. Once the positioning of the implant is verified, light is delivered through a proprietary fiber to cure the monomer for rapid stabilization of the bone. This results in a customized fit to each patient’s specific anatomy providing rotational and torsional stability to the fracture. PBSS can be implanted for stand-alone primary fixation or in combination with screws or plates.
“This strong and growing IP portfolio demonstrates that we are continuing to advance our innovative fracture fixation technologies as we expand our commercial efforts in Europe and work towards gaining regulatory approval in the United States,” said Robert Rabiner, founder and chief technology officer of IlluminOss. “With the addition of these three new patents, we can confidently say that our IP portfolio covers the whole body.”
Dirk Kuyper, president and CEO of IlluminOss, said, “In addition to the robustness of our patent estate, IluminOss is gathering compelling clinical evidence that shows how our patient-customized approach to fracture repair has the potential to improve clinical outcomes.”
IlluminOss was founded in 2007 and is headquartered in East Providence, Rhode Island. The company currently markets its products under a CE Mark in Austria, Germany, Israel, Italy, the Netherlands, Spain, Switzerland and Turkey.